A randomised, phase II study of repeated rhenium-188-HEDP combined with docetaxel and prednisone versus docetaxel and prednisone alone in castration-resistant prostate cancer (CRPC) metastatic to bone; the Taxium II trial-Reference-Cited by-同舟云学术

A randomised, phase II study of repeated rhenium-188-HEDP combined with docetaxel and prednisone versus docetaxel and prednisone alone in castration-resistant prostate cancer (CRPC) metastatic to bone; the Taxium II trial

Published:2017-04-18 Issue:8 Volume:44 Page:1319-1327
ISSN:1619-7070
Container-title:European Journal of Nuclear Medicine and Molecular Imaging
language:en
Short-container-title:Eur J Nucl Med Mol Imaging

Author:

van Dodewaard-de Jong Joyce M.,de Klerk John M. H.,Bloemendal Haiko J.,Oprea-Lager Daniela E.,Hoekstra Otto S.,van den Berg H. Pieter,Los Maartje,Beeker Aart,Jonker Marianne A.,O’Sullivan Joe M.,Verheul Henk M. W.,van den Eertwegh Alfons J. M.

Funder

KWF Kankerbestrijding

Publisher

Springer Science and Business Media LLC

Subject

Radiology, Nuclear Medicine and imaging,General Medicine,Radiology, Nuclear Medicine and imaging,General Medicine

Link

http://link.springer.com/article/10.1007/s00259-017-3673-9/fulltext.html

Reference20 articles.

1. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502–12.

2. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513–20.

3. Van Dodewaard-de Jong JM, Verheul HMW, Bloemendal HJ, et al. New treatment options for patients with metastatic prostate cancer: what is the optimal sequence? Clin Genitourin Cancer. 2015;13:271–9.